November 2023 Medical News Summary
JAMA Medical News - Un podcast de JAMA Network - Les vendredis
Why Physicians Don’t Deprescribe Medicines; What to Know About Wegovy’s Rare but Serious Adverse Effects; What to Know About Zepbound, the Newest Antiobesity Drug Related Content: As Semaglutide’s Popularity Soars, Rare but Serious Adverse Effects Are Emerging FDA Green-Lights Tirzepatide, Marketed as Zepbound, for Chronic Weight Management Deciding When It’s Better to Deprescribe Medicines Than to Continue Them
